Cold remedy makers publicizing safety of non-PPA substances

Published: 2004-08-12 07:00:00

Updated: 2004-08-12 07:00:00

With growing public anger over the belated response of the Korea Food and Drug Administration to prohibit 167 cold remedies containing phenylpropanolamine (PPA), a number of pharmaceutical firms are making desperate efforts to publicize the fact that their non-PPA cold remedies are safe and effec...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK